Akums Drugs and Pharmaceuticals Ltd - 544222 - Receipt Of Assessment Order(S) From Income Tax Department
Akums Drugs & Pharma and its subsidiary Akumentis Healthcare Ltd. have received assessment orders from the Income Tax Department for a total demand of Rs.133.75 crore. The company believes the demand is not sustainable and plans to appeal the orders.
May 20 2026 19:05:00
Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Akums Drugs & Pharma has made available the audio recording of its investors/analysts conference call held on May 18, 2026. The call discussed the unaudited financial results for Q4 FY26 and audited results for FY26. The transcript will be uploaded later.
May 18 2026 17:05:00
Akums Drugs and Pharmaceuticals Ltd - 544222 - Update On Disruption In Operations At Some Of The Manufacturing Sites At Haridwar
Akums Drugs & Pharma has fully resumed manufacturing operations at its Haridwar sites, effective May 18, 2026. A four-day disruption had resulted in a delayed supply of approximately Rs.20 crore, which the company expects to recover.
May 18 2026 12:05:00
Akums Drugs and Pharmaceuticals Ltd - 544222 - Intimation Of Disruption In Operations At Some Of The Manufacturing Sites At Haridwar
Akums Drugs & Pharma reported temporary disruption of manufacturing operations at some Haridwar sites due to labour unrest on May 14, 2026. The company is actively working with authorities and workers to normalize operations.
May 14 2026 16:05:00
Akums Drugs and Pharmaceuticals Ltd - 544222 - Corporate Action-Board approves Dividend
Akums Drugs & Pharma recommended a total dividend of ₹3.00 per equity share for FY26, comprising a final dividend of ₹1.00 and a special dividend of ₹2.00. The record date is July 3, 2026.
May 14 2026 14:05:00
Akums Drugs and Pharmaceuticals Ltd - 544222 - Recommendation Of Final Cum Special Dividend
Akums Drugs & Pharma received show cause notices from the Income Tax Department for disallowance of expenses, stemming from a search and seizure operation in January 2025. This matter was noted by the auditor as an 'Emphasis of Matter', indicating potential unquantified financial impact.
May 14 2026 13:05:00
Akums Drugs and Pharmaceuticals Ltd - 544222 - Board Meeting Outcome for Outcome Of Board Meeting For Financial Results
Akums Drugs & Pharma Board approved FY26 consolidated financial results, reporting ₹4,487.74 crore revenue (up 7.6% YoY) and ₹256.40 crore net profit (down 25.4% YoY). A total dividend of ₹3.00 per share was recommended, with July 03, 2026, as the record date. The board also appointed new internal auditors and confirmed changes in senior HR management.
May 14 2026 13:05:00
Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Akums Drugs will conduct an analyst and investor conference call on May 18, 2026, to discuss its Q4 and full-year FY26 financial results. The virtual call will feature presentations from key management personnel, including the MDs, CFO, and Head Strategy.
May 12 2026 20:05:00
Akums Drugs and Pharmaceuticals Ltd - 544222 - Board Meeting Intimation for Board Meeting Intimation
Akums Drugs & Pharma's Board of Directors will convene on May 14, 2026, to consider and approve the audited financial results for Q4 FY26 and the full financial year. Additionally, the board will recommend a dividend, if any, for FY26.
May 11 2026 23:05:00
Akums Drugs and Pharmaceuticals Ltd - 544222 - Execution Of Lease Deed
Akums Drugs' wholly-owned subsidiary, Pure and Cure Healthcare, acquired an industrial plot of approximately 4050 Sq. Mtrs in Haridwar, Uttarakhand. This plot is adjacent to the existing manufacturing facility and will support the subsidiary's business operations.
Apr 29 2026 17:04:00
Read More